Our research has, for the first time, demonstrated that the upregulation of ASF1B can simultaneously activate both the PI3K/AKT and ERK1/2 signaling pathways, further underscoring the value of ASF1B as a potential therapeutic target in GC. Here, AKT1 is linked to gastric cancer.